Cargando…

Myeloablative Temozolomide Enhances CD8(+) T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice

Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be incompatible with immunotherapy. Conversely,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanchez-Perez, Luis A., Choi, Bryan D., Archer, Gary E., Cui, Xiuyu, Flores, Catherine, Johnson, Laura A., Schmittling, Robert J., Snyder, David, Herndon, James E., Bigner, Darell D., Mitchell, Duane A., Sampson, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601076/ https://www.ncbi.nlm.nih.gov/pubmed/23527092 http://dx.doi.org/10.1371/journal.pone.0059082

Ejemplares similares

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
por: Flores, Catherine, et al.
Publicado: (2015)

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
por: Sampson, John H., et al.
Publicado: (2012)

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells()
por: Cui, Bo, et al.
Publicado: (2010)

A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system
por: Choi, Bryan D., et al.
Publicado: (2013)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
por: Miao, Hongsheng, et al.
Publicado: (2014)

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
por: Suryadevara, Carter M., et al.
Publicado: (2018)

Toxin-Based Targeted Therapy for Malignant Brain Tumors
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2012)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Enzyme Redesign Guided by Cancer-Derived IDH1 Mutations
por: Reitman, Zachary J., et al.
Publicado: (2012)

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
por: Mitchell, Duane A., et al.
Publicado: (2015)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Monitoring Radiographic Brain Tumor Progression
por: Mehta, Ankit I., et al.
Publicado: (2011)

Imaging of Convection Enhanced Delivery of Toxins in Humans
por: Mehta, Ankit I., et al.
Publicado: (2011)

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
Publicado: (2022)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
por: Stephens, Sarah J., et al.
Publicado: (2016)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Comparison of Non-myeloablative Conditioning Regimens for Lymphoproliferative Disorders
por: Hong, Sanghee, et al.
Publicado: (2014)

Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue.
por: Dunlop, D. J., et al.
Publicado: (1994)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET)
por: Gururangan, Sridharan, et al.
Publicado: (2020)

Aberrant Otx2 Expression Enhances Migration and Induces Ectopic Proliferation of Hindbrain Neuronal Progenitor Cells
por: Wortham, Matthew, et al.
Publicado: (2012)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
por: Kanaly, Charles W., et al.
Publicado: (2011)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity
por: Mosaheb, Mubeen M., et al.
Publicado: (2020)

Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Targeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
por: Böttcher, Chotima, et al.
Publicado: (2013)

Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis
por: Wang, Lai, et al.
Publicado: (2015)

Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model
por: Uchida, Naoya, et al.
Publicado: (2023)

Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma
por: Gholamin, Sharareh, et al.
Publicado: (2019)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES
por: Wilkinson, Daniel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qnvngh30t4o8vf5v1pk3djcne0